Drug Profile
Research programme: stem cell therapeutics - GlaxoSmithKline/Harvard Stem Cell Institute
Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Harvard Stem Cell Institute
- Developer GSK; Harvard Stem Cell Institute
- Class Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer; Cardiovascular disorders; Diabetes mellitus; Musculoskeletal disorders; Neurological disorders; Obesity
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for research development in Cancer in USA
- 04 Nov 2017 No recent reports of development identified for research development in Cardiovascular-disorders in USA
- 04 Nov 2017 No recent reports of development identified for research development in Diabetes-mellitus in USA